TrianglePUBLICATIONS · 22465830
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Clin Cancer Res
- Publication date
- 2012 May 1
- First author
- Naing A
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Naing A
- type
- Author
- name
- LoRusso P
- type
- Author
- name
- Fu S
- type
- Author
- name
- Hong DS
- type
- Author
- name
- Anderson P
- type
- Author
- name
- Benjamin RS
- type
- Author
- name
- Ludwig J
- type
- Author
- name
- Chen HX
- type
- Author
- name
- Doyle LA
- type
- Author
- name
- Kurzrock R
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Naing A
- type
- Author
- name
- LoRusso P
- type
- Author
- name
- Fu S
- type
- Author
- name
- Hong DS
- type
- Author
- name
- Anderson P
- type
- Author
- name
- Benjamin RS
- type
- Author
- name
- Ludwig J
- type
- Author
- name
- Chen HX
- type
- Author
- name
- Doyle LA
- type
- Author
- name
- Kurzrock R
- type
- Author
- bibliography ids
- nci-bib-456470cac5db44b9c825615e
- book metadata
- content sha256
- 628c45e8f25a170bb2ee53e4b0537d7344e253ffb85390edb5c04933b15e730c
- document type
- citation
- dois
- 10.1158/1078-0432.CCR-12-0061
- electronic publication date
- display
- 2012 Mar 31
- precision
- day
- year
- 2012
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:22465830
- immutable id
- pubmed:22465830@628c45e8f25a170bb2ee53e4b0537d7344e253ffb85390edb5c04933b15e730c
- journal
- abbreviation
- Clin Cancer Res
- issn electronic
- 1557-3265
- issn print
- 1078-0432
- issue
- 9
- name
- Clinical cancer research : an official journal of the American Association for Cancer Research
- nlm unique id
- 9502500
- pages
- 2625-31
- volume
- 18
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 22465830
- provenance
- batch id
- c95be1d0b8cf19942816
- provider
- NCBI PubMed ESummary
- record sha256
- 740c1420787fe75f863ecfa0d69d6c9c8e238579fc2b8716c046bedf047e7911
- response sha256
- a96bb680a8f3690267e009557d1b07aab71455ba44aeba18695d98a3eeb5fcf2
- retrieved at
- 2026-09-09T23:46:47.691937+00:00
- publication date
- display
- 2012 May 1
- precision
- day
- year
- 2012
- publication types
- Clinical Trial, Phase I
- Journal Article
- Research Support, N.I.H., Extramural
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Preserved source evidence · Not medical advice